<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04368546</url>
  </required_header>
  <id_info>
    <org_study_id>ChariteU-ECRC-TSS2</org_study_id>
    <secondary_id>EA1/044/15</secondary_id>
    <nct_id>NCT04368546</nct_id>
  </id_info>
  <brief_title>Sunitinib Treatment on Tissue Sodium Accumulation (TSS2)</brief_title>
  <official_title>Effect of Sunitinib Treatment on Tissue Sodium Accumulation in Patients With Renal Cancer: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Heart Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Here, it is investigated how sunitinib, a tyrosine kinase-inhibitor targeting vascular
      endothelial growth factor receptors, might influence sodium homeostasis in the skin and if
      this is related to a well-described treatment side-effect of sunitinib, hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tyrosine kinases-inhibitors targeting vascular endothelial growth factor (VEGF)-receptors
      (RTKIs) are increasingly used in oncology in several metastatic tumor types. These agents are
      featured by toxicities including hypertension. According to a new insight, sodium in response
      to a high dietary sodium intake, is accumulated in a hyperosmolar way in the interstitial
      compartment. In response to this high sodium concentration cells of the mononuclear
      phagocytic system (MPS) are activated resulting in an increased production of VEGF-C,
      activation of VEGF type 3 receptors and formation of a lymphatic capillary network, involved
      in clearance of interstitial sodium. Blockade of stimulation of VEGF-C receptors or depletion
      of MPS cells in rodents has been associated with salt-sensitive hypertension.

      Sunitinib is an orally-active, multitarget RTKI mainly used for the treatment of patients
      with metastatic renal cancer and imatinib-resistant gastrointestinal stromal tumors.
      Sunitinib blocks all three VEGF receptors subtypes, including VEGF-receptor type 3.

      The investigators hypothesize that treatment of patients with sunitinib is associated with
      tissue sodium accumulation and this accumulation contributes to the rise in blood pressure.
      Tissue sodium is measured by using a newly developed 23Na magnetic resonance-imaging (MRI)
      technique which allows a non-invasive and contrast agent-free sodium content measurement in
      the muscle and skin of the lower leg.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 1, 2015</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">February 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Skin sodium</measure>
    <time_frame>3 months (before, 4 weeks on, 2 weeks off and 4 weeks on medication)</time_frame>
    <description>Changes in sodium content measured by 23Na magnetic resonance-imaging (MRI) technique</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma VEGF-C</measure>
    <time_frame>3 months (before, 4 weeks on, 2 weeks off and 4 weeks on medication)</time_frame>
    <description>Concentration of VEGF-C in patients plasma</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">6</enrollment>
  <condition>Renal Cell Cancer Metastatic</condition>
  <condition>Hypertension</condition>
  <condition>Sodium Imbalance</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Metastatic cell carcinoma patients before sunitinib treatment, after 4 week on, after 2 week off and finally again 4 week on medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Age-matched subjects without known disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <arm_group_label>Patients</arm_group_label>
    <other_name>Diagnostic test: 23Na-MRI</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with metastatic renal cell carcinome in the primary care of the Charité -
        Universitätsmedizin Berlin as well as healthy subjects without known disease recruited in
        the Charité - Universitätsmedizin Berlin and healthy volunteers form the Max-Delbrück
        Center of Molecular Medicine
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age men &gt; 18 years

          -  Life-expectation &gt; 3 months

          -  Stable weight

          -  Blood pressure below 140/90 mmHg at baseline

          -  Estimated glomerular filtration rate &gt; 45 ml/min/1.73m2

          -  Willingness to give written informed consent

        Exclusion Criteria:

          -  Heart failure

          -  Liver disease with ascites

          -  Nephrotic syndrome

          -  Gastrointestinal complaints, preventing normal daily food intake or diarrhea

          -  Any form of diabetes mellitus

          -  Known autoimmune diseases

          -  Acute or chronic infection

          -  Alcohol or substance abuse
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>The effect of the female hormonal cycle on skin sodium homeostasis is unknown, therefore we include here male subjects only.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominik Müller, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Group leader at the Max Delbruck Center for Molecular Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Experimental and Clinical Research Center, Clinical Research Unit</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Kandula P, Agarwal R. Proteinuria and hypertension with tyrosine kinase inhibitors. Kidney Int. 2011 Dec;80(12):1271-7. doi: 10.1038/ki.2011.288. Epub 2011 Sep 7. Review.</citation>
    <PMID>21900879</PMID>
  </reference>
  <reference>
    <citation>Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, van den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension. 2010 Oct;56(4):675-81. doi: 10.1161/HYPERTENSIONAHA.109.149690. Epub 2010 Aug 23.</citation>
    <PMID>20733093</PMID>
  </reference>
  <reference>
    <citation>Machnik A, Neuhofer W, Jantsch J, Dahlmann A, Tammela T, Machura K, Park JK, Beck FX, Müller DN, Derer W, Goss J, Ziomber A, Dietsch P, Wagner H, van Rooijen N, Kurtz A, Hilgers KF, Alitalo K, Eckardt KU, Luft FC, Kerjaschki D, Titze J. Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat Med. 2009 May;15(5):545-52. doi: 10.1038/nm.1960. Epub 2009 May 3.</citation>
    <PMID>19412173</PMID>
  </reference>
  <reference>
    <citation>Kopp C, Linz P, Dahlmann A, Hammon M, Jantsch J, Müller DN, Schmieder RE, Cavallaro A, Eckardt KU, Uder M, Luft FC, Titze J. 23Na magnetic resonance imaging-determined tissue sodium in healthy subjects and hypertensive patients. Hypertension. 2013 Mar;61(3):635-40. doi: 10.1161/HYPERTENSIONAHA.111.00566. Epub 2013 Jan 21.</citation>
    <PMID>23339169</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Dr. Lajos Marko</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Sunitinib</keyword>
  <keyword>Tyrosine kinases-inhibitor</keyword>
  <keyword>Sodium</keyword>
  <keyword>MRI</keyword>
  <keyword>Skin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

